Atlas Trials

Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

Clinical trial NCT00098098 · COMPLETED

Trial details

NCT number
NCT00098098
Sponsor
DynPort Vaccine Company LLC, A GDIT Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
RECOMBINANT BOTULINUM VACCINE A/B
Start date
2004-08-01
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.